Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-2-OLE: Open-Label Extension of Deramiocel in Duchenne Muscular Dystrophy
NCT04428476Phase 2Active, not recruiting
- Sponsor
- Capricor Therapeutics
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of deramiocel in Duchenne muscular dystrophy (DMD), sponsored by Capricor Therapeutics. Started Aug 2020; status: active, not recruiting.
02
Drugs
deramiocel
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04428476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428476.